Mobilisation and Reinfusion of Philadelphia Negative Peripheral Blood Mononuclear Cells in Chronic Myeloid Leukaemia with Hydroxyurea and G-CSF

References

• Allan N. C., Richards S. M., Shepherd P. C. UK Medical Research Council randomised, multicentre trial of interferon‐alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Anonymous. Interferon alfa‐2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia [see comments]. New England Journal of Medicine 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Kolb H. J., Heinze B., Hochhaus A., Griesshammer M., Pralle H., Queisser W. P., Essers U., Falge C., et al. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leukemia & Lymphoma 1993; 11: 159–168, Suppl
   PubMed Web of Science ®Google Scholar
• McGlave P., Bartsch G., Anasetti C., Ash R., Beatty P., Gajewski J., Kernan N. A. Unrelated donor marrow transplantation therapy for chronic myeloid leukaemia: Initial experience of the national marrow donor program. Blood 1993; 81: 543–550
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Biggs J. C., Bortin M. M. Bone marrow transplantation for chronic myelogenous leukaemia in chronic phase: increased risk of relapse associated with T‐cell depletion. Annals of Internal Medicine 1988; 108: 806–814
   PubMed Web of Science ®Google Scholar
• Mackinnon S. Detection of residual disease following T‐cell depleted allogeneic BMT for CML. implications for autografting of a loss of GVL effect. Bone Marrow Transplantation 1994; 14(Suppl 3)88
   Google Scholar
• Cross N. C., Feng L., Bungey J., Goldman J. M. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leukemia & Lymphoma 1993; 11(Suppl 1)39–43
   PubMed Web of Science ®Google Scholar
• Simonsson B., Oberg G., Killander A., Bjoreman M., Borkholm M., Gahrton G., Hast R., Turesson I., Uden A. M., Malm C., et al. Intensive treatment in order to minimize the Ph‐positive clone in chronic myelogenic leukemia. Stem Cells 1993; 11: 73–76, Suppl
   PubMed Web of Science ®Google Scholar
• Carella A. M., Frassoni F., Negrin R. S. Autografting in chronic myelogenous leukemia: new questions [editorial]. Leukemia 1995; 9: 365–369
   PubMed Web of Science ®Google Scholar
• Carella A. M., Frassoni F., Podesta M., Saglio G. Eradication of the Philadelphia chromosome‐positive clone and persistent restoration of normal polyclonal haemopoiesis in a chronic myelogenous leukemia patient after autologous transplant with peripheral blood Philadelphia‐negative haemopoietic cells [letter]. Bone Marrow Transplantation 1994; 13: 668–669
   PubMedGoogle Scholar
• Carella A. M., Podesta M., Frassoni F., Pungolino E., Pollicardo N., Raffo M. R., Ferrero R., Benvenuto F., Figari O., Giordano D., et al. Selective overshoot of Ph‐negative blood hemopoietic cells after intensive idarubicin‐containing regimen and their repopulating capacity after reinfusion. Stem Cells 1993; 11: 67–72, Suppl
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Goldman J. M. Autologous transplant for CML revisited. [Review]. Experimental Hematology 1993; 21: 734–737
   PubMed Web of Science ®Google Scholar
• Goldman J. M. Autografting for CML‐where does it fit in to the overall treatment strategy? [Review]. Bone Marrow Transplantation 1994; 14(Suppl 3)S74–S77
   PubMedGoogle Scholar
• O'Brien S. G., Goldman J. M. Current approaches to hematopoietic stem‐cell purging in chronic myeloid leukemia [editorial]. [Review]. Journal of Clinical Oncology 1995; 13: 541–546
   PubMed Web of Science ®Google Scholar
• Finney R., McDonald G. A., Baikie A. G. Chronic granulocytic leukaemia with Ph negative cells in bone marrow and a ten year remission after busulphan hypoplasia. British Journal of Haematology 1972; 23: 283–288
   PubMed Web of Science ®Google Scholar
• Sharp J. C., Joyner M. V., Wayne A. W. Karyotypic conversion in Ph positive chronic myeloid leukaemia with combination chemotherapy. Lancet 1979; 1: 1370–1372
   PubMed Web of Science ®Google Scholar
• McGlave P. B., De Fabritiis P., Deisseroth A., Goldman J., Barnett M., Reiffers J., Simonsson B., Carella A., Aeppli D. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486–1488
   PubMed Web of Science ®Google Scholar
• Mughal T., Hoyle C., Goldman J. M. Autografting for patients with chronic myeloid leukemia‐the Hammersmith experience. Stem Cells 1993; 11: 20–22, Suppl
   PubMed Web of Science ®Google Scholar
• O'Brien S. G., Goldman J. M. Autografting in chronic myeloid leukaemia. [Review]. Blood Reviews 1994; 8: 63–69
   PubMed Web of Science ®Google Scholar
• Eaves C. J., Barnett M. J., Eaves A. C. In vitro culture of bone marrow cells for autografting in CML. Leukemia 1993; 7(Suppl 2)S126–S129
   PubMedGoogle Scholar
• Barnett M. J., Eaves C. J., Phillips G. L., Hogge D. E., Klingemann H. G., Lansdorp P. N., Nantel S. H., Reece D. E., Shepherd J. D., Sutherland H. J., et al. Autografting in chronic myeloid leukemia with cultured marrow: update of the Vancouver study. Stem Cells 1993; 11(Suppl 3)64–66
   PubMedGoogle Scholar
• O'Brien S. G., Kirkland M. A., Melo J. V., Rao M. H., Davidson R. J., McDonald C., Goldman J. M. Antisense BCR‐ABL oligomers cause non‐specific inhibition of chronic myeloid leukemia cell lines. Leukemia 1994; 8(12)2156–2162
   PubMed Web of Science ®Google Scholar
• Carella A. M., Gaozza E., Raffo M. R. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 1991; 5: 517–521
   PubMed Web of Science ®Google Scholar
• Carella A. M., Frassoni F., Pollicardo N., Pungolino E., Podesta M., Giordano D., Ferrero R., Soracco M., Benvenuto F., Figari O. Ph‐negative blood progenitor cells (BPCs) can be recruited after chemotherapy and G‐CSF during early hemopoietic recovery in patients at diagnosis of CML or pretreated only with hydroxyurea. Bone Marrow Transplantation 1994; 14(Suppl 3)S34–S37
   PubMedGoogle Scholar
• Carella A. M., Podesta M., Frassoni F., Raffo M. R., Pollicardo N., Pungolino E., Vimercati R., Sessarego M., Parodi C., Rabitti C., et al. Collection of ‘normal’ blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplantation 1993; 12: 267–271
   PubMed Web of Science ®Google Scholar
• Carella A. M., Pollicardo N., Pungolino E., Raffo M. R., Podesta M., Ferrero R., Pierluigi D., Nati S., Naibo K., Congiu A., et al. Mobilization of cytogenetically ‘normal’ blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leukemia & Lymphoma 1993; 9: 477–483
   PubMed Web of Science ®Google Scholar
• Chalmers E. A., Franklin I. M., Kelsey S., Clark R., Sprout A. M., Goldstone A. H., Hepplestone A., Watson W., Sharp S., Tansey P. Mobilisation of Ph‐negative peripheral blood stem cells in CML with Idarubicin and cytarabine. Bone Marrow Transplantation 1994; 14(Suppl 3)38–42
   Google Scholar
• Goldman J. M., O'Brien A. G. Residual Ph negative stem cells in chronic myeloid leukaemia‐sometimes or always?. Stem Cells 1993; 11: 4–7, Suppl
   PubMed Web of Science ®Google Scholar
• Carella A. M., Frassoni F., Podesta M., Pungolino E., Pollicardo N., Ferrero R., Soracco M. Idarubicin, intermediate‐dose cytarabine, etoposide, and granulocyte‐colony‐stimulating factor are able to recruit CD34+/HLA‐DR‐cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia. Journal of Hematotherapy 1994; 3: 199–202
   PubMedGoogle Scholar
• Carella A. M., Frassoni F. ICE, mini‐ICE or high dose Hydroxyurea to mobilise Philadelphia (Ph1)‐negative PBPC in Chronic Myelogenous Leukaemia (CML) [LETTER]. British Journal of Haematology 1996, IN PRESS
   Google Scholar
• Hazel D. L., Kelsey S. M., Baksh N., Gutteridge C. N., Cavengh J. D., Gale R., Newland A. C. Peripheral blood stem cell transplantation (PBSCT) for chronic granulocytic leukaemia. British Journal of Haematology 1996; 93(Suppl 1)17, abstr. 66
   Google Scholar
• Lennard A. L., Storey N., Dickinson A. M., Irving J. A., Rowe D., Dunn J., Proctor S. J. Is there a future for peripheral blood progenitor cell mobilisation and transplantation in CML?. British Journal of Haematology 1996; 93(Suppl 1)15, abstr. 58
   Google Scholar
• Sureda A., Brunet A., Martino R., Amill B., Aventin A., Sanchez J. A., Madoz P., Garcia‐Lopez J., Domingo‐Albos A. Mobilisation of Haematopoietic progenitor cells in chronic myeloid leukemia patients by ICE chemotherapy plus G‐CSF. Blood 1995; 86(Suppl 1)405a, 1609, abstr.
   Google Scholar
• Kantarjian H. M., Talpaz M., Hester J., Feldman E., Korbling M., Liang J., Rios M. B., Smith T. L., Calvert L., Deisseroth A. B. Collection of peripheral‐blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive‐dose chemotherapy. Journal of Clinical Oncology 1995; 13(3)553–9
   PubMed Web of Science ®Google Scholar
• Butler M., Larkins S., Kyei Mensah P., Simpson A., McDonald D., Boughton B. Peripheral blood stem cells (PBSC) harvested post chemotherapy for autologous bone marrow transplantation (ABMT) in chronic granulocytic leukaemia. Stem Cells 1993; 11(Suppl 3)135
   Google Scholar
• Henon P. R., Eisenmann J. C., Becker M., Beck‐Wirth G., Wunder E., Sovalat H. Difficulties in collecting peripheral blood stem cells in chronic myeloid leukemia related to persistence of the leukemic cell clone. Stem Cells 1993; 11(Suppl 3)43–47
   PubMedGoogle Scholar
• Talpaz M., Kantarjian H., Hester J., Champlin R., Deisseroth A. Autologous “in vivo” purged bone marrow and peripheral blood stem cell transplant in chronic myelogenous leukemia (CML): induction of cytogenetic response and interferon alpha responsiveness. Blood 1993; 82 Suppl 1: 1495
   Google Scholar
• Tringali S., Santoro A., Scime R., Vasta S., Pampinella M., Marino M. A., Majolino I. High‐dose cyclophosphamide for mobilization of circulating stem cells in chronic myeloid leukemia. European Journal of Haematology 1994; 53(1)1–5
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K., Queisser W., Loffler H., Heinze B., Georgii A., et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993; 82: 398–407
   PubMed Web of Science ®Google Scholar
• Kolitz J. E., Kempin S. J., Schluger A., Wong G. Y., Berman E., Jhanwar S., Arlin Z. A., Gee T., Clarkson B. D. A phase II pilot trial of high‐dose hydroxyurea in chronic myelogenous leukemia. Seminars in Oncology 1992; 19: 27–33, Suppl
   PubMed Web of Science ®Google Scholar
• Kuss B. J., Sage R. E., Shepherd K. M., Hardingham J., Nicola M. High dose of hydroxyurea in collection of Philadelphia chromosome‐negative stem cells in chronic myeloid leukaemia. Leukemia & Lymphoma 1993; 10: 73–78
   PubMed Web of Science ®Google Scholar
• Johnson R. J., Owen R. G., Child J. A., Morgan G. J., Barnard D. L., Dickinson H., Ricketts S., Rawstron A. C., Evans P. A., Woodhead V., Major K., Robinson F., Smith G. M. Mobilisation of Philadelphia negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G‐CSF (Filgrastim). British Journal of Haematology 1996; 93: 863–868
   PubMed Web of Science ®Google Scholar
• Liu Yin J. A., Nagesh K., Lenehan H., Brereton M., Lucas G. S. Harvesting of Ph1‐ve PBSC after high dose Hydroxyurea in chronic phase CML. British Journal of Haematology 1996; 93(Suppl 1)17, abstr. 65
   Google Scholar
• Treleaven J., Powles R., Singhal S., Swansbury G. J., Millar B., Shepherd V., Bell J., Min T., Cabral S., Mehta J. High dose Hydroxyurea and G‐CSF to collect Philadelphia‐negative cells in chronic myeloid leukemia. Blood 1995; 86(Suppl 1)405a, abstr. 1608
   Google Scholar
• Brenner M. K., Rill D. R., Moen R. C., Krance R. A., Mirro J., Jr., Anderson W. F., Ihle J. N. Gene‐marking to trace origin of relapse after autologous bone‐marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Cogswell P. C., Morgan R., Dunn M. Mutations of the Ras protooncogenes in chronic myelogenous leukaemia: a high frequency of Ras mutations in bcr/abl rearrangement‐negative cases. Blood 1989; 74: 2629–2633
   PubMed Web of Science ®Google Scholar
• Ferraris A. M., Canepa L., Melani C., Miglino M., Broccia G., Gaetani G. F. Clonal B lymphocytes lack bcr rearrangement in Ph‐positive chronic myelogenous leukaemia. British Journal of Haematology 1989; 73: 48–50
   PubMed Web of Science ®Google Scholar
• Lisker R., Casas L., Mutchinik O., Perez‐Chavez F., Labardini J. Late appearing Philadelphia chromosome in 2 patients with chronic myelogenous leukaemia. Blood 1980; 56: 812–814
   PubMed Web of Science ®Google Scholar
• Hogge D. E., Coulombel L., Kalousek D. K., Eaves C. J., Eaves A. C. Non clonal haematopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukaemia revealed after long term marrow culture. American Journal of Haematology 1987; 24: 389–394
   PubMed Web of Science ®Google Scholar
• Zhang Y., Poetsch M., Weber‐Matthiesen K., Rohde K., Winkemann M., Haferlach T., Gassmann W., Ludwig W. D., Grote W., Loffler H., Schlegelberger B. Secondary acute leukaemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies. British Journal of Haematology 1996; 92(3)673–680
   PubMed Web of Science ®Google Scholar
• Weber‐Matthiesen K., Deerberg J., Poetsch M., Grote W., Schlegelberger B. Clarification of dubious karyotypes in Hodgkin's disease by simultaneous fluorescence immunophenotyping and interphase cytogenetics (FICTION). Cytogenetics & Cell Genetics 1995; 70(3–4)243–245
   PubMedGoogle Scholar
• Inaba T., Shimazaki C., Tatsumi T., Yamagata N., Hirata T., Goto H., Fujita N., Nakagawa M. Expression of differentiation‐associated antigens and adhesion molecules on CD34‐positive cells harvested from peripheral blood and bone marrow. Progress in Clinical & Biological Research 1994; 389: 331–337
   PubMedGoogle Scholar